Suscribirse

Associations of elevated Interleukin-6 and C-Reactive protein levels with mortality in the elderly - 08/09/11

Doi : 10.1016/S0002-9343(99)00066-2 
Tamara B Harris, MD, MS a, , Luigi Ferrucci, MD, PhD b, Russell P Tracy, PhD c, M.Chiara Corti, MD, PhD d, Sholom Wacholder, PhD e, Walter H Ettinger, MD, MBA f, Harley Heimovitz, MS g, Harvey J Cohen, MD h, Robert Wallace, MD, MSc i
a Epidemiology, Demography and Biometry Program (TBH), National Institute on Aging, Bethesda, Maryland, USA 
b National Research Institute (INRCA) (LF), Florence, Italy 
c University of Vermont (RPT), Burlington, Vermont, USA 
d University of Padova (MCC), Padova, Italy 
e National Cancer Institute (SW), Bethesda, Maryland, USA 
f Bowman Gray School of Medicine (WHE), Winston-Salem, North Carolina, USA 
g Sytel (HH), Bethesda, Maryland, USA 
h Duke University School of Medicine (HJC), Durham, North Carolina, USA 
i University of Iowa College of Medicine (RW), Iowa City, Iowa, USA 

*Requests for reprints should be addressed to Tamara B. Harris, MD, MS, Epidemiology, Demography and Biometry Program, National Institute on Aging, Gateway Building, Room 3C-309, 7201 Wisconsin Avenue, Bethesda, Maryland 20892-9205

Abstract

PURPOSE: To investigate whether interleukin-6 and C-reactive protein levels predict all-cause and cause-specific mortality in a population-based sample of nondisabled older people.

SUBJECTS AND METHODS: A sample of 1,293 healthy, nondisabled participants in the Iowa 65+ Rural Health Study was followed prospectively for a mean of 4.6 years. Plasma interleukin-6 and C-reactive protein levels were measured in specimens obtained from 1987 to 1989.

RESULTS: Higher interleukin-6 levels were associated with a twofold greater risk of death [relative risk (RR) for the highest quartile (≥3.19 pg/mL) compared with the lowest quartile of 1.9 [95% confidence interval, CI, 1.2 to 3.1]). Higher C-reactive protein levels (≥2.78 mg/L) were also associated with increased risk (RR = 1.6; CI, 1.0 to 2.6). Subjects with elevation of both interleukin-6 and C-reactive protein levels were 2.6 times more likely (CI, 1.6 to 4.3) to die during follow-up than those with low levels of both measurements. Similar results were found for cardiovascular and noncardiovascular causes of death, as well as when subjects were stratified by sex, smoking status, and prior cardiovascular disease, and for both early (<2.3 years) and later follow-up. Results were independent of age, sex, body mass index, and history of smoking, diabetes, and cardiovascular disease, as well as known indicators of inflammation including fibrinogen and albumin levels and white blood cell count.

CONCLUSIONS: Higher circulating levels of interleukin-6 and C-reactive protein were associated with mortality in this population-based sample of healthy older persons. These measures may be useful for identification of high-risk subgroups for anti-inflammatory interventions.

El texto completo de este artículo está disponible en PDF.

Esquema


 Supported in part by National Institute on Aging Contract AG-0-2106. This paper was finalized when Drs. Ferrucci and Corti were Visiting Scientists in the Epidemiology, Demography and Biometry Program at the National Institute on Aging.


© 1999  Excerpta Medica Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 106 - N° 5

P. 506-512 - mai 1999 Regresar al número
Artículo precedente Artículo precedente
  • Successful implementation of guidelines for encouraging the use of beta blockers in patients after acute myocardial infarction
  • François P Sarasin, Maria-Luisa Maschiangelo, Marie-Denise Schaller, Céliane Héliot, Sandrine Mischler, Jean-Michel Gaspoz
| Artículo siguiente Artículo siguiente
  • A randomized, double-blind comparison of risedronate and etidronate in the treatment of paget’s disease of bone
  • Paul D Miller, Jacques P Brown, Ethel S Siris, Mohammad S Hoseyni, Douglas W Axelrod, Pirow J Bekker, for the Paget’s Risedronate/Etidronate Study Group

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.